Welcome to the 571st Critical Care Reviews Newsletter, bringing you the best critical care research and open access articles from across the medical literature over the past week.
The highlights of this week's edition are randomised controlled trials comparing the respective effects of helmet pressure support, continuous positive airway pressure and nasal high-flow in hypoxemic respiratory failure & evaluating the anti–GM-CSF agent Otilimab in severe COVID-19 pneumonia; systematic reviews and meta analyses on extracorporeal carbon dioxide removal in acute hypoxaemic respiratory failure & beta-lactam antibiotic therapeutic drug monitoring in critically ill patients; and observational studies on in-hospital and 6-month outcomes in patients with COVID-19 supported with ECMO & COVID-19 and excess all-cause mortality in the USA and 20 comparison countries.
There are also guidelines on the hyperosmolar hyperglycaemic state & near hanging; narrative reviews on fluids in the ICU & ventilator-associated events; editorials on the future for inotropes in heart failure & agitated patients in the ICU; and commentaries on adjustment for baseline characteristics in randomized clinical trials & an introduction to hemodynamic forces by echocardiography; as well as correspondence on defining ARDS (Again).
If you only have time to read one review article this week, try this one on how to integrate hemodynamic variables during resuscitation of septic shock.
Discounted hotel rates for delegates for the Critical Care Reviews Meeting 2023 (June 14th to 16th) are now available on the CCR23 webpage. The meeting is on in peak tourist season so don't delay too long before booking your accommodation. Hotel rooms will be hard to find closer to the time. There will also be a writing workshop on Tuesday, June 13th. More details will be available in the next newsletter.
You can support Critical Care Reviews, from as little as the price of a cup of coffee per month or make a one-off donation. We are not-for-profit and make all our content free to view. Our aim is to share science for the benefit of all - please join us in this mission.
I hope you find this newsletter useful.
Until next week